• DoD should pursue and encourage research to map the epitopes of the protective antigen that correlate with specific functional activities;

  • DoD should pursue and encourage research to test the therapeutic potential of antitoxin proteins or antibodies; and

  • DoD should pursue and encourage research into additional potential virulence factors in B. anthracis and into other possible vaccine candidates.

REFERENCES

Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans . Vaccine 20(9-10):1412-1420.


Schwartz B. 2002. Hypothesis testing using the DMSS: outline for a CDC-AMSA collaboration. Presentation to the Institute of Medicine Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, Meeting V, Washington, D.C.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement